Androgen Effects in HIV-infected Women
HIV Infection
About this trial
This is an interventional treatment trial for HIV Infection focused on measuring HIV, women, androgen, Treatment Experienced
Eligibility Criteria
Inclusion Criteria: Female 18 - 55 BMI less than or equal to 26 HIV-infected Androgen deficient, with free testosterone < 3 pg/mL Stable antiretroviral regimen for 3 months prior to study Tubal ligation, hysterectomy, or verbalized understanding of appropriate barrier contraception methods. Subjects will be counseled in appropriate barrier contraception methods and the counseling will be documented. Exclusion Criteria: Use of anabolic agent, including testosterone, GH or other preparations within 3 months of the study. Use of megestrol acetate within 3 months of the study Use of estrogen or any preparation known to affect bone density or bone turnover.This includes oral contraceptives, depo provera or combined progesterone-estrogen injections, and transdermal contraceptive patches. Pregnant or breast-feeding Hgb < 9.0 mg/dL Current participation in another research study conducted by this investigator or past participation in the DHEA study funded by the same grant as this protocol. Creatinine > 1.5 mg/dL
Sites / Locations
- Mass General Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
1 Transdermal Testosterone (Patch)
2 Placebo Patch (identical in appearance)
300 micrograms applied twice a week
placebo patch (0 micrograms of testosterone)applied twice a week